Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559031 | 0.92 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL9313461 | 0.92 | PPARG (0.70) | AGTR1AGTR2 | |
| SCHEMBL21083612 | 0.91 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL8565668 | 0.90 | AGTR1 (0.62) | AGTR1AGTR2 | |
| SCHEMBL21124815 | 0.90 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL9301037 | 0.89 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL8872802 | 0.89 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL21125174 | 0.88 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL29726823 | 0.88 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL21125187 | 0.88 | AGTR1 (0.55) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0480659-B1 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | claimed |
| US-5260322-A | Angiotension II antagonists in the treatment of hyperuricemia | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | claimed |
| EP-0480659-A2 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885AGTR2 2610/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885AGTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.